Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902476 | 0.82 | KDM4E (0.60) | HDAC1KDM4ENPC1GLAMAPT | |
| SCHEMBL6880927 | 0.77 | HDAC1 (0.41) | HDAC1KDM4ENPC1GLAMAPT | |
| SCHEMBL6854322 | 0.77 | HDAC1 (0.41) | HDAC1KDM4ENPC1GLAMAPT | |
| SCHEMBL3904118 | 0.77 | HDAC1 (0.38) | HDAC1KDM4ENPC1GLAMAPT | |
| SCHEMBL6854070 | 0.74 | HDAC3 (0.41) | HDAC1KDM4EMAPT | |
| SCHEMBL6852407 | 0.74 | PIK3CD (0.33) | KDM4ENPC1GLAMAPTRAB9A | |
| SCHEMBL6852131 | 0.74 | CYP2A6 (0.53) | HDAC1KDM4EMAPT | |
| SCHEMBL13722910 | 0.74 | HDAC1 (0.36) | HDAC1KDM4ENPC1GLAMAPT | |
| SCHEMBL6852454 | 0.70 | LTA4H (0.44) | HDAC1KDM4ENPC1GLAMAPT | |
| SCHEMBL6156613 | 0.70 | TRPM8 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | claimed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | claimed |
| EP-1501519-A1 | 9-OXIME MACROLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1501846-A1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1499326-A1 | OXOLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | claimed |
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | claimed |
| WO-2003093289-A1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2003-11-13 | — | — | WO | claimed |
| WO-2003090760-A1 | OXOLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | claimed |
| WO-2003090761-A1 | 9-OXIME MACROLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | claimed |
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | disclosed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | disclosed |
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1501519-A1 | 9-OXIME MACROLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501846-A1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| WO-2003093289-A1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003090760-A1 | OXOLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003090761-A1 | 9-OXIME MACROLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | CYP2C9, CYP1B1, SULT1E1 | HDAC1 117/4885KDM4E 2482/4885NPC1 421/4885 |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | RPN1, CASP1, MRPL21 | HDAC1 23/4885KDM4E 4677/4885NPC1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.